[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"covid-19-infection\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:covid-19-infection":26},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,11,0,[8,59,85,108,128,148,167,191,220,244,271],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":27,"overallStatus":46,"whyStopped":4,"lastUpdateSubmitDate":47,"lastUpdatePostDateStruct":48,"startDateStruct":51,"completionDateStruct":53,"leadSponsor":55,"locationsCount":58},"100593979","phase-3-a-study-to-learn-about-the-study-medicine-ibuzatrelvir-in-adults-with-covid-19-who-are-severely-immunocompromised-100593979",false,"NCT07013474","A Study to Learn About the Study Medicine Ibuzatrelvir in Adults With COVID-19 Who Are Severely Immunocompromised","AN INTERVENTIONAL EFFICACY AND SAFETY, PHASE 3, RANDOMIZED, DOUBLE-BLIND, 3-ARM STUDY TO INVESTIGATE IBUZATRELVIR IN ADULTS WITH SYMPTOMATIC COVID-19 WHO ARE SEVERELY IMMUNOCOMPROMISED","Inclusion Criteria:\n\n1. 18 years of age or older at screening who are non-hospitalized or hospitalized for observation or with the intent of administering the study intervention.\n2. Confirmed SARS-CoV-2 infection as determined by RAT (or other locally approved test) collected within 2 days prior to randomization. Initial onset of symptoms attributable to COVID-19 within 5 days prior to the day of randomization and at least 1 of the specified symptoms attributable to COVID-19 present on the day of randomization.\n3. Severely immunocompromised due to:\n\n   * Solid organ or islet cell transplant recipient who is receiving immunosuppressive therapy;\n   * Active hematologic malignancy (eg, chronic lymphocytic leukemia, non-Hodgkin lymphoma, multiple myeloma, acute leukemia);\n   * Receipt of CAR-T-cell therapy or HCT either within 2 years of transplantation or who are receiving immunosuppressive therapy;\n   * Currently receiving or recently received B-cell depleting therapies (eg, rituximab), where the immunosuppressive effect is still ongoing.\n\nExclusion Criteria:\n\n1. Severe COVID-19, or current need for supplemental oxygen for treatment of COVID-19.\n2. Receiving dialysis or have current kidney failure (ie, eGFR consistently \\\u003C15 mL\u002Fmin\u002F1.73 m2)\n3. Active liver disease\n4. History of hypersensitivity or other contraindication to any of the components of the study interventions, as determined by the investigator\n5. Suspected or confirmed concurrent active systemic infection other than COVID-19 that may interfere with the evaluation of response to the study intervention.\n6. Life expectancy less than 30 days at study entry due to an underlying condition, in the judgement of the investigator.\n7. Any medical or psychiatric condition including recent (within the past year) or active suicidal ideation\u002Fbehavior or laboratory abnormality that may increase the risk of study participation or, in the investigator's judgment, make the participant inappropriate for the study.\n8. Has received any other antiviral for the treatment of the current COVID-19 infection\n9. Current use of any prohibited concomitant medication(s) or unwillingness or inability to use a required concomitant medication(s).\n10. Current or previous administration of an investigational product (drug or vaccine) within 30 days (or as determined by local requirement) or 5 half lives preceding the first dose of study intervention used in this study (whichever is longer). Authorized or products with conditional approval are not considered investigational.\n11. Prior participation in this trial or any clinical trial of ibuzatrelvir.\n12. Females who are pregnant, breastfeeding, or who are planning to become pregnant within the timeframe of the study.\n13. Investigator site staff directly involved in the conduct of the study and their family members, site staff otherwise supervised by the investigator, and sponsor and sponsor delegate employees directly involved in the conduct of the study and their family members.","ALL","18 Years",{"count":19,"type":20},300,"ESTIMATED","INTERVENTIONAL",[23],"PHASE3","This is a Phase 3, randomized, actively controlled, double-blinded, double-dummy, superiority study to evaluate the efficacy and safety of ibuzatrelvir alone and in combination with remdesivir IV compared to remdesivir IV alone for the treatment of symptomatic COVID-19 in severely immunocompromised adult participants who are non-hospitalized or are hospitalized for observation or study intervention administration but do not require supplemental oxygen for COVID-19.",[26],"COVID-19 Infection",[28,29,30,31,32,33,34,35,36,37,38,39,40,41,42,43,44,45],"COVID-19 infection","pneumonia","respiratory tract infections","coronavirus infection","RNA virus infection","lung disease","pneumonia, viral","infections","virus","viral protease inhibitor","protease inhibitor","enzyme inhibitor","severe immunocompromise","anti-viral agents","anti-infectives","ibuzatrelvir","remdesivir","COVID-19","RECRUITING","2026-06-29",{"date":49,"type":50},"2026-07-01","ACTUAL",{"date":52,"type":50},"2025-07-14",{"date":54,"type":20},"2028-02-25",{"name":56,"class":57},"Pfizer","INDUSTRY",148,{"id":60,"slug":61,"hasResults":11,"nctId":62,"briefTitle":63,"officialTitle":64,"acronym":4,"eligibilityCriteria":65,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":66,"enrollmentInfo":67,"targetDuration":4,"studyType":69,"phases":4,"briefSummary":70,"conditions":71,"keywords":4,"overallStatus":46,"whyStopped":4,"lastUpdateSubmitDate":74,"lastUpdatePostDateStruct":75,"startDateStruct":77,"completionDateStruct":79,"leadSponsor":81,"locationsCount":84},"100404823","the-effect-of-covid-19-pandemic-on-adolescent-and-young-adult-cancer-patients-and-survivors-100404823","NCT04551378","The Effect of COVID-19 Pandemic on Adolescent and Young Adult Cancer Patients and Survivors","Impacts of Coronavirus Disease 2019 (COVID-19) Pandemic on Adolescent and Young Adult (AYA) Cancer Patients and Survivors","Inclusion Criteria:\n\n* PATIENT COHORT INCLUSION:\n* Initial cancer diagnosis between the ages of 15 to 39\n* Received any cancer treatment at MD Anderson Cancer Center with data available in the MD Anderson Cancer Center Tumor Registry\n* For questionnaire provision: confirmed alive at time of contact\n\nExclusion Criteria:\n\n* PATIENT COHORT EXCLUSION:\n* Inability to complete questionnaires in English\n* Seen at MD Anderson for a second opinion or non-treatment related visit","39 Years",{"count":68,"type":20},600,"OBSERVATIONAL","The study investigates how the COVID-19 pandemic has impacted the psychological, financial, physical, and social well-being of adolescent and young adult (AYA) cancer patients and survivors. AYA cancer survivors have inferior long-term survival compared to the general population, and the negative impact of the global COVID-19 pandemic may be even higher in this vulnerable group. The information gained from this study may provide an opportunity to determine the self-reported COVID-19 specific psychological distress in AYA cancer survivors, and may lead to the development of a targeted intervention to improve physical and psychosocial health for AYA cancer patients and survivors.",[26,72,73],"Hematopoietic and Lymphoid Cell Neoplasm","Malignant Solid Neoplasm","2026-05-29",{"date":76,"type":50},"2026-06-02",{"date":78,"type":50},"2020-07-13",{"date":80,"type":20},"2028-12-31",{"name":82,"class":83},"M.D. Anderson Cancer Center","OTHER",1,{"id":86,"slug":87,"hasResults":11,"nctId":88,"briefTitle":89,"officialTitle":90,"acronym":4,"eligibilityCriteria":91,"healthyVolunteers":11,"sex":92,"minAge":17,"maxAge":4,"enrollmentInfo":93,"targetDuration":4,"studyType":69,"phases":4,"briefSummary":94,"conditions":95,"keywords":4,"overallStatus":46,"whyStopped":4,"lastUpdateSubmitDate":99,"lastUpdatePostDateStruct":100,"startDateStruct":102,"completionDateStruct":104,"leadSponsor":106,"locationsCount":107},"100375518","impact-of-covid-19-pandemic-on-out-of-pocket-costs-lost-wages-and-unemployment-in-patients-with-breast-cancer-undergoing-breast-surgery-100375518","NCT04169542","Impact of COVID-19 Pandemic on Out-of-Pocket Costs, Lost Wages, and Unemployment in Patients With Breast Cancer Undergoing Breast Surgery","Potential Impact of the COVID -19 Pandemic on Financial Toxicity in Breast Cancer Surgical Patients: The Impact on Out of Pocket Costs, Lost Wages and Economic Strain","Inclusion Criteria:\n\n* Have an indication for surgical treatment of invasive breast cancer or ductal breast carcinoma in situ (DCIS) or prophylaxis in the setting of genetic mutations or strong family history\n* English-speaking\n* Able to complete consent\n* Able to fill out computer survey material\n\nExclusion Criteria:\n\n* Non-English-speaking\n* Those with recurrent or metastatic disease or concurrent primary cancers\n* Patients undergoing breast conservation therapy will also be excluded from the study","FEMALE",{"count":68,"type":20},"This study investigates the impact of COVID-19 pandemic on out-of-pocket costs, lost wages, and unemployment in patients with breast cancer undergoing breast surgery. Post-mastectomy reconstructive patients are at high risk for financial toxicity (adverse effects of escalating health care cost on well-being). The goal of this study is to collect information about financial costs patients may have as a result of surgical treatment for cancer with or without breast reconstruction and to learn if COVID-19 affects patient costs of breast reconstruction. This may help researchers demonstrate the financial consequences of undergoing breast surgery.",[96,26,97,98],"Breast Ductal Carcinoma In Situ","Hereditary Breast Carcinoma","Invasive Breast Carcinoma","2026-04-28",{"date":101,"type":50},"2026-05-04",{"date":103,"type":50},"2019-05-21",{"date":105,"type":20},"2028-03-31",{"name":82,"class":83},4,{"id":109,"slug":110,"hasResults":11,"nctId":111,"briefTitle":112,"officialTitle":113,"acronym":4,"eligibilityCriteria":114,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":115,"targetDuration":4,"studyType":69,"phases":4,"briefSummary":117,"conditions":118,"keywords":4,"overallStatus":46,"whyStopped":4,"lastUpdateSubmitDate":120,"lastUpdatePostDateStruct":121,"startDateStruct":123,"completionDateStruct":125,"leadSponsor":127,"locationsCount":84},"100398910","well-being-and-health-related-quality-of-life-in-melanoma-patients-during-covid-19-pandemic-100398910","NCT04474301","Well-Being and Health-Related Quality of Life in Melanoma Patients During COVID-19 Pandemic","Well-Being and Quality of Life in Melanoma Patients During COVID-19 Pandemic","Inclusion Criteria:\n\n* Patients who have signed consent for PA15-0336\n* Has an active email address and can be contacted via MyChart\n* Documentation of being alive per the cancer registry",{"count":116,"type":20},1152,"The primary purpose of this study is to gain an understanding of how experiences during the COVID-19 pandemic, regardless of COVID-19 status, may have impacted multiple domains of health-related quality of life and other areas such as COVID-19 specific psychological distress, and disruptions to health care, finances and social interactions. We will also evaluate the extent to which resiliency factors such as social support, perceived benefits under times of stress, and ability to manage stress may buffer associations between COVID-19 experiences and HRQoL. To meet these objectives, we have developed a 10-minute questionnaire that taps into these areas and is based on prior work addressing concerns of other pandemics or national crises. Participants will have previously consented to protocol PA15-0336 and have provided prior lifestyle data. This will allow us to connect the COVID-19 survey data with prior existing data.",[26,119],"Melanoma","2026-04-13",{"date":122,"type":50},"2026-04-16",{"date":124,"type":50},"2020-06-11",{"date":126,"type":20},"2026-12-30",{"name":82,"class":83},{"id":129,"slug":130,"hasResults":11,"nctId":131,"briefTitle":132,"officialTitle":133,"acronym":4,"eligibilityCriteria":134,"healthyVolunteers":135,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":136,"targetDuration":4,"studyType":69,"phases":4,"briefSummary":138,"conditions":139,"keywords":4,"overallStatus":46,"whyStopped":4,"lastUpdateSubmitDate":140,"lastUpdatePostDateStruct":141,"startDateStruct":143,"completionDateStruct":145,"leadSponsor":147,"locationsCount":84},"100440986","the-impact-of-covid-19-on-pulmonary-procedures-100440986","NCT05022446","The Impact of COVID-19 on Pulmonary Procedures","The Impact of COVID-19 on Pulmonary Procedures: A Nationwide Survey","Inclusion Criteria:\n\n* Pulmonologists that are members of the American Association of Bronchology and Interventional Pulmonology (AABIP) and\u002For the American College of Chest Physicians (ACCP)\n* These organizations were chosen because their member databases are composed of pulmonologists in the United States (U.S.) that perform the pulmonary procedures described in this survey. Letters of approval will be obtained from these organizations and provided to the MD Anderson Institutional Review Board (IRB). Once the MD Anderson IRB approves this survey study, the survey will be sent to the relevant subcommittees of these organizations for their electronic dissemination to their membership\n\nExclusion Criteria:\n\nNone",true,{"count":137,"type":20},250,"This study investigates the changes in practice by pulmonary procedural programs across the United States as they faced the coronavirus pandemic. Information gathered from this study may help guide pulmonary programs on a wider scale and improve their practice. The study may also help researchers understand where they should focus research efforts to better respond to a pandemic in the future.",[26,72,73],"2026-02-11",{"date":142,"type":50},"2026-02-13",{"date":144,"type":50},"2020-11-11",{"date":146,"type":20},"2027-02-02",{"name":82,"class":83},{"id":149,"slug":150,"hasResults":11,"nctId":151,"briefTitle":152,"officialTitle":153,"acronym":4,"eligibilityCriteria":154,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":155,"targetDuration":4,"studyType":69,"phases":4,"briefSummary":157,"conditions":158,"keywords":4,"overallStatus":46,"whyStopped":4,"lastUpdateSubmitDate":159,"lastUpdatePostDateStruct":160,"startDateStruct":162,"completionDateStruct":164,"leadSponsor":166,"locationsCount":84},"100400212","assessment-of-the-psychosocial-impact-of-the-covid-19-pandemic-on-the-md-anderson-cancer-center-workforce-100400212","NCT04491292","Assessment of the Psychosocial Impact of the COVID-19 Pandemic on the MD Anderson Cancer Center Workforce","Psychosocial Impact of COVID-19 Pandemic on MD Anderson Workforce","Inclusion Criteria:\n\n* MD Anderson employees",{"count":156,"type":20},20000,"This study investigates the impact of the COVID-19 pandemic on the psychosocial health of employees of MD Anderson Cancer Center. Epidemics have been shown to promote psychological stress among medical staff in high risk areas, which may lead to mental health problems. Assessing how the pandemic is affecting employees may allow for more comprehensive actions to be taken to protect the mental health of employees.",[26],"2026-01-26",{"date":161,"type":50},"2026-01-28",{"date":163,"type":50},"2020-05-18",{"date":165,"type":20},"2026-04-30",{"name":82,"class":83},{"id":168,"slug":169,"hasResults":11,"nctId":170,"briefTitle":171,"officialTitle":172,"acronym":173,"eligibilityCriteria":174,"healthyVolunteers":135,"sex":16,"minAge":17,"maxAge":175,"enrollmentInfo":176,"targetDuration":4,"studyType":21,"phases":178,"briefSummary":180,"conditions":181,"keywords":4,"overallStatus":46,"whyStopped":4,"lastUpdateSubmitDate":182,"lastUpdatePostDateStruct":183,"startDateStruct":184,"completionDateStruct":186,"leadSponsor":188,"locationsCount":190},"100545425","phase-2-a-trial-of-a-next-generation-covid-19-vaccine-delivered-by-inhaled-aerosol-100545425","NCT06381739","A Trial of a Next Generation COVID-19 Vaccine Delivered by Inhaled Aerosol","A Phase 2 Trial to Evaluate Safety and Immunogenicity of a Next-generation COVID-19 Vaccine Delivered by Inhaled Aerosol to Humans","AeroVax","Inclusion criteria:\n\n1. Adults who are 18-65 years old on the day of randomization (day 1)\n2. Able to read, write and communicate using the English or French language.\n3. Received at least 3 doses of an mRNA COVID vaccine.\n4. Individuals of childbearing potential must have a negative pregnancy test prior to vaccination and be willing to practice effective contraception for 8 weeks post-vaccination.\n5. Able to understand and comply with protocol requirements and instructions; able to report adverse events; able to attend scheduled study visits and complete required investigations.\n6. For participants in the BAL sub-study, Complete Blood Count (CBC) and chemistry (creatinine) within normal limits.\n7. For participants in the BAL sub-study, forced expiratory volume in 1 second (FEV1) \\> the lower limit of normal (LLN), and FEV1\u002FFVC (forced expiratory volume in 1 second\u002Fforced vital capacity) ratio above the LLN.\n8. Agree not to enroll in any other intervention studies for the duration of the study where the intervention could be reasonably expected to be associated with adverse events overlapping with the inhaled vaccine or the immune responses being measured.\n\nExclusion criteria:\n\n1. Failure to provide informed consent.\n2. Women who are pregnant or breastfeeding.\n3. Have received any recombinant adenoviral-vectored COVID-19 vaccine (AstraZeneca \\[Vaxzeria\\] or Johnson \\& Johnson (Janssen Jcovden).\n4. COVID infection (positive PCR or antigen (Ag) test, self-reported or lab documented) within the last 90 days.\n5. Last dose of a COVID vaccine administered less than 90 days prior to study entry.\n6. Administration of any vaccine within 2 weeks of study entry.\n7. Active pulmonary disease diagnosed by a physician including asthma, chronic bronchitis, interstitial lung disease, pulmonary hypertension, lung cancer, cystic fibrosis, or bronchiectasis. Current use of daily inhaled steroids for any condition.\n8. Persons with HIV and a detectable HIV viral load (\\>20 copies\u002FmL), self-reported or confirmed.\n9. Administration of monoclonal antibodies for treatment of COVID-19 infection within 3 months.\n10. Moderately or severely immunocompromised (e.g. transplant recipients\u002FCAR-T cell therapy, currently on chemotherapy for cancer or on potent immunosuppressant therapies e.g. rituximab or high dose steroids \\[\\>30 mg of prednisone equivalent daily\\], or moderate or severe primary immunodeficiency syndrome).\n11. History of severe reaction to previous COVID vaccination (e.g. hives, difficulty breathing, high fever, seizures, myocarditis, pericarditis)).\n12. Potential contraindication to COVID vaccination (e.g. venous or arterial thrombosis with thrombocytopenia after vaccination, history of cerebral venous thrombosis with thrombocytopenia, history of heparin induced thrombocytopenia, history of myocarditis or pericarditis).\n13. Known allergy to vaccine components or previous receipt of any experimental adenovirus-vector vaccine by the aerosol route.\n14. Enrolment in any clinical trial of experimental treatment for COVID infection within 90 days.\n15. For participants in the BAL sub-study, any health-related condition for which study bronchoscopy is contraindicated.\n16. For participants in the BAL sub-study, current use of anticoagulants.","65 Years",{"count":177,"type":20},350,[179],"PHASE2","The goal of this clinical trial is to study the safety of a new inhaled vaccine to prevent COVID infection and learn about the immune responses that are made in the lungs and the blood after vaccination. Participants will be randomized (like the toss of a coin) to receive the experimental vaccine or a placebo (a look-alike solution that contains no vaccine).\n\nTo be in the study participants will have to have already had three doses of a messenger ribonucleic acid (mRNA) COVID vaccine and be generally healthy. Participants are given a single dose of the vaccine by breathing in a fine mist that goes directly into the lungs.\n\nDuring follow-up participants will:\n\n* visit the clinic for checkups and blood tests at 2, 4 and 8 weeks after vaccination\n* report their symptoms for 24 weeks after getting the vaccine.\n\nIn some participants, the researchers will collect cells from the lung 4 weeks after vaccination (a test known as a bronchoscopy).",[26],"2026-01-22",{"date":159,"type":50},{"date":185,"type":50},"2025-03-25",{"date":187,"type":20},"2027-01",{"name":189,"class":83},"McMaster University",2,{"id":192,"slug":193,"hasResults":11,"nctId":194,"briefTitle":195,"officialTitle":196,"acronym":4,"eligibilityCriteria":197,"healthyVolunteers":135,"sex":16,"minAge":198,"maxAge":199,"enrollmentInfo":200,"targetDuration":4,"studyType":69,"phases":4,"briefSummary":202,"conditions":203,"keywords":204,"overallStatus":46,"whyStopped":4,"lastUpdateSubmitDate":182,"lastUpdatePostDateStruct":211,"startDateStruct":213,"completionDateStruct":215,"leadSponsor":217,"locationsCount":84},"100407244","send-in-sample-collection-for-comprehensive-analyses-of-innate-and-adaptive-immune-responses-during-acute-covid-19-and-convalescence-100407244","NCT04582903","Send-In Sample Collection for Comprehensive Analyses of Innate and Adaptive Immune Responses During Acute COVID-19 and Convalescence","Send-In Sample Collection for Comprehensive Analyses of Innate and Adaptive Immune Responses During Acute Infections With, and Convalescence From, Emerging or Re-emerging Respiratory Viruses","* INCLUSION CRITERIA:\n\nParticipants enrolled onto this protocol must meet all of the following criteria:\n\n1. Aged 0-99 years (including viable neonates).\n2. Meets one of the following criteria:\n\n   1. Patient with a known or suspected diagnosis of infection (past or current) with SARS-CoV-2 or an emerging or re-emerging respiratory virus, typically but not always supported by a positive PCR test for viral RNA;\n   2. Individual who has remained uninfected with negative virus serologies despite heavy or extensive exposure to the emerging or re-emerging respiratory virus in the workplace or home environment; or\n   3. Biological relative of a participant being studied under this protocol. Relatives may be biological mother, father, siblings, children, grandparents, aunts, uncles, or first cousins.\n3. For individuals considered for enrollment as uninfected individuals and biological relatives, able to provide informed consent.\n4. Willing to allow genetic testing.\n5. Willing to allow storage of samples and data for future research.\n\nEXCLUSION CRITERIA:\n\nIndividuals meeting any of the following criteria will be excluded from study participation:\n\n1\\. Any condition that, in the opinion of the investigator, contraindicates participation in this study.\n\nSince patients can be concurrently infected with multiple respiratory viruses, positive testing for other viruses such as rhinovirus, influenza virus, etc., does not exclude an individual from study participation where there remains a high clinical suspicion of infection with the emerging or re-emerging respiratory virus of interest despite negative testing for it.\n\nCo-enrollment guidelines: Participants may be co-enrolled in other studies; however, study staff should be notified of co-enrollment.","1 Day","99 Years",{"count":201,"type":20},5000,"Background:\n\nSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2) causes coronavirus disease 2019 (COVID-19). The global outbreak of COVID-19 is a major public health problem. COVID-19 causes a wide range of symptoms. These symptoms range from mild breathing problems to life-threatening problems or death. Some people have no symptoms. This study aims to learn how acute and late immune responses to COVID-19 lead to different outcomes. The immune system is the body s defense against germs, including viruses, that invade the body.\n\nObjective:\n\nTo characterize the immune responses during and after SARS-CoV-2 infection and determine if there is any relationship to clinical course and outcome.\n\nEligibility:\n\nPeople ages 0 99 who have confirmed or suspected SARS-CoV-2 infection, people who are not infected despite heavy exposure, and relatives of enrolled participants.\n\nDesign:\n\nThis is a sample collection protocol to receive send-in biological specimens for exploratory studies, including gene testing. Participants will not be seen at the NIH for study visits.\n\nStudy staff will talk with participants health care providers to screen them for the study. Participants enrolled into the protocol will send samples and clinical information at least once and more often if the participant has COVID-19. All participants will provide blood samples and possibly stool. We may also ask for left over specimens from any medical procedures completed as part of medical care. The study staff will also request participants health care providers to complete a survey to collect demographic and medical data. Some of this information may need to be provided directly by the participant.\n\nPregnant individuals are invited to participate and may be asked to give cord blood samples after delivery. Study findings that affect participants health may be shared with their health care provider. Depending on findings, participants may be contacted to take part in other NIH studies.",[26],[205,206,207,208,209,210],"severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)","Repository","Pandemic","Genetics","Proteomics","Natural History",{"date":212,"type":50},"2026-01-23",{"date":214,"type":50},"2020-10-13",{"date":216,"type":20},"2031-01-31",{"name":218,"class":219},"National Institute of Allergy and Infectious Diseases (NIAID)","NIH",{"id":221,"slug":222,"hasResults":11,"nctId":223,"briefTitle":224,"officialTitle":225,"acronym":4,"eligibilityCriteria":226,"healthyVolunteers":135,"sex":92,"minAge":17,"maxAge":4,"enrollmentInfo":227,"targetDuration":4,"studyType":69,"phases":4,"briefSummary":228,"conditions":229,"keywords":234,"overallStatus":46,"whyStopped":4,"lastUpdateSubmitDate":235,"lastUpdatePostDateStruct":236,"startDateStruct":238,"completionDateStruct":240,"leadSponsor":242,"locationsCount":84},"100481801","researchers-at-uc-san-diego-are-learning-about-the-benefits-of-human-milk-and-how-it-influences-infant-and-child-health-100481801","NCT05553743","Researchers At UC San Diego Are Learning About the Benefits of Human Milk and How It Influences Infant and Child Health","The UCSD Human Milk Biorepository","Inclusion Criteria:\n\n* Women who are 18 years old or older\n* Breastfeeding\n* Producing sufficient breast milk to donate an excess to the Biorepository\n\nExclusion Criteria:\n\n* Women under 18 years old",{"count":201,"type":20},"The purpose of the UCSD Human Milk Biorepository is to establish and maintain a repository of breast milk samples that can be used to learn more about how breast milk influences infant and child health.",[230,26,231,232,233],"Breastfeeding","COVID-19 Vaccine","Remdesivir","Antibiotics",[230,26,231,232,233],"2025-01-28",{"date":237,"type":50},"2025-01-31",{"date":239,"type":50},"2014-03-27",{"date":241,"type":20},"2040-03",{"name":243,"class":83},"University of California, San Diego",{"id":245,"slug":246,"hasResults":11,"nctId":247,"briefTitle":248,"officialTitle":249,"acronym":4,"eligibilityCriteria":250,"healthyVolunteers":135,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":251,"targetDuration":4,"studyType":21,"phases":252,"briefSummary":254,"conditions":255,"keywords":256,"overallStatus":46,"whyStopped":4,"lastUpdateSubmitDate":262,"lastUpdatePostDateStruct":263,"startDateStruct":265,"completionDateStruct":267,"leadSponsor":269,"locationsCount":84},"100531020","integrated-mindfulness-based-health-qigong-intervention-for-covid-19-survivors-and-caregivers-100531020","NCT06194357","Integrated Mindfulness-based Health Qigong Intervention for COVID-19 Survivors and Caregivers","Developing an Integrated Mindfulness-based Health Qigong Intervention (iMBHQ) for COVID-19 Survivors and Caregivers to Improve Their Physical and Psychological Wellness","Inclusion Criteria:\n\n* COVID-19 survivors: people aged 18 years or above who were infected by COVID-19 (both symptomatic and asymptomatic) and clinically recovered\n* Caregivers of COVID-19 patients, including family members or medical professionals who have contacts with patients diagnosed COVID-19 aged 18 years or above\n* General healthy public aged 18 years or above\n\nExclusion Criteria:\n\n* people diagnosed severe and\u002For chronic conditions that prevent the practice of Qigong (e.g., acute exacerbation of dyspnoea, severe cardiopulmonary disease) or mindfulness intervention,\n* people with severe psychiatric disorder\n* people who have regular psychiatric follow-ups",{"count":68,"type":20},[253],"NA","COVID-19-related depression, anxiety, and stigma are expected to have short-term and long-term adverse impacts on mental health, help seeking and preventive behaviours in affected individuals, including care providers and the general population. Health qigong (HQ), a form of traditional Chinese martial arts with emphasis placed on the body movement and status of mind, has been demonstrated to enhance both physical and mental health. Mindfulness-based interventions (MBIs), another mind-body treatment, have become increasingly popular for treating a number of health problems. This study proposes an integrated intervention that combines the effects of HQ and MBIs (iMBHQ) to improve the mental wellbeing of COVID-19 survivors, caregivers including healthcare providers and family members as well as the general public in the community.",[26],[257,258,259,260,261],"COVID-19 Survivors","caregivers","mindfulness-based health Qigong intervention","physical wellness","psychological wellness","2024-01-04",{"date":264,"type":50},"2024-01-08",{"date":266,"type":50},"2023-01-30",{"date":268,"type":20},"2026-09-30",{"name":270,"class":83},"The Hong Kong Polytechnic University",{"id":272,"slug":273,"hasResults":11,"nctId":274,"briefTitle":275,"officialTitle":275,"acronym":276,"eligibilityCriteria":277,"healthyVolunteers":135,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":278,"targetDuration":4,"studyType":69,"phases":4,"briefSummary":279,"conditions":280,"keywords":4,"overallStatus":46,"whyStopped":4,"lastUpdateSubmitDate":282,"lastUpdatePostDateStruct":283,"startDateStruct":285,"completionDateStruct":287,"leadSponsor":289,"locationsCount":84},"100498733","evaluation-of-covid-19-immune-barrier-and-reinfection-risk-100498733","NCT05774093","Evaluation of COVID-19 Immune Barrier and Reinfection Risk","COVID","Inclusion Criteria:\n\n1. No age limit, no gender limit;\n2. Medical staff, administrative and logistics staff who work in the Third Affiliated Hospital of Sun Yat-Sen University or other participants who can cooperate with the follow-up for 48 weeks;\n3. The participants need to be sure whether they have ever been infected with COVID-19, and need to be clearly remember the time when they first infected with COVID-19.\n\nExclusion Criteria:\n\n1. Have the following serious respiratory diseases: such as asthma, bronchiectasis, chronic obstructive pulmonary disease, pulmonary interstitial disease, tuberculosis and other respiratory diseases that may interfere with symptom observation;\n2. Those with other serious diseases or disease history that affect immune function, including but not limited to uncontrolled and unresectable malignant tumors,hematological diseases, cachexia, active bleeding, severe malnutrition, mental diseases, autoimmune diseases, HIV, etc.\n3. Those who have long-term assignment plans and cannot return to the hospital regularly for follow-up.",{"count":19,"type":20},"The goal of this observational study is to evaluate the protective effect of immune barrier on secondary infection after COVID-19 (coronavirus disease 2019) vaccination or COVID-19 virus Omicron B A. 5.2 strain infection by dynamically monitoring the COVID-19 antibody titer, cellular immune function and the occurrence of secondary infection of healthy participants, mainly medical staff in our hospital, to understand the cross protective effect of COVID-19 antibody on different variants of Omicron, and explore the best time to use COVID-19 vaccine to strengthen immunity after Omicron mutant infection.",[26,281],"Immunization; Infection","2023-03-15",{"date":284,"type":50},"2023-03-17",{"date":286,"type":50},"2023-03-06",{"date":288,"type":20},"2027-07-31",{"name":290,"class":83},"Sun Yat-sen University"]